IKT (Inhibikase Therapeutics) Short Percentage of Float


IKT Inhibikase Therapeutics Inc IKT
33 GF Score
Price $1.89
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IKT vs NKTX, CAMP, NERV: Short Percentage of Float Comparison

For the Biotechnology subindustry, Inhibikase Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Short Percentage of Float falls into.


IKT
33GF Score
Inhibikase Therapeutics Inc IKT
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score

Get the complete analysis for IKT

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.89
Price